Prelude Therapeutics Inc
PRLD Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.70
KIRA · Stoqly’s AI analyst, in plain words
- Prelude Therapeutics Inc had $12.1M of revenue in fiscal 2025, up 73.4% on the year before.
- Its operating margin was −861.3%, up 1,134.6 pts: of every 100 in sales, about −861 is left after running the business.
- Prelude Therapeutics Inc lost $99.5M in fiscal 2025.
- Free cash flow was −$56.4M in fiscal 2025, −464.3% of revenue.
Market cap
$364M
P/E
—
Revenue
$12.1M
Net income
−$99.5M
Free cash flow
−$56.4M
Operating margin
−861.3%
Prelude Therapeutics Inc in 30 seconds · fiscal 2025
Are sales growing?
+73.4%
Yes. Sales grew 73.4% last year.
Does it make a profit?
−819.6%
No. It lost money last year.
Does profit turn into cash?
−464.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Prelude Therapeutics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Prelude Therapeutics Inc
- CIK
- 0001678660
Prelude Therapeutics Inc · PRLD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $7.0M | $12.1M |
| Revenue growth | — | — | — | — | 73.4% |
| Operating margin | — | — | — | −1,995.9% | −861.3% |
| Net income | −$112M | −$115M | −$122M | −$127M | −$99.5M |
| Net margin | — | — | — | −1,816.8% | −819.6% |
| Diluted EPS | −$2.43 | −$2.44 | −$2.02 | −$1.68 | −$1.29 |
| Cash | |||||
| Cash from operations | −$83.5M | −$83.7M | −$107M | −$103M | −$56.3M |
| Capital expenditure | $2.3M | $3.0M | $3.5M | $0.8M | $0.1M |
| Free cash flow | −$85.9M | −$86.7M | −$111M | −$104M | −$56.4M |
| FCF margin | — | — | — | −1,480.7% | −464.3% |
| Share count change | 269.0% | 2.9% | 27.4% | 25.6% | 1.5% |
| Debt and strength | |||||
| Cash and short-term investments | $291M | $202M | $233M | $134M | $103M |
| Shareholders' equity | $286M | $195M | $237M | $131M | $68.6M |
| Current ratio | 15.4x | 9.4x | 10.8x | 5.3x | 2.0x |
| Returns and quality | |||||
| Return on equity | −44.8% | −48.0% | −56.3% | −69.0% | −99.5% |
| Return on tangible equity | −39.1% | −59.1% | −51.4% | −96.7% | −145.0% |
| Piotroski F-score | — | — | — | — | 3 |
| Altman Z'' | 16.7 | 4.9 | 2.6 | −8.9 | −17.3 |
Insiders bought, 12 months
$25.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prelude Therapeutics Inc · PRLD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.70 a share, the company is worth $364M.
Source: SEC EDGAR XBRL filings (CIK 0001678660). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.